Patrick Marcellin

Summary

Country: France

Publications

  1. doi request reprint Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection
    Patrick Marcellin
    Hopital Beaujon, Clichy, France Electronic address
    Gastroenterology 145:790-800.e3. 2013
  2. doi request reprint High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Hepatology 56:2039-50. 2012
  3. doi request reprint Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
  4. doi request reprint Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients
    Patrick Marcellin
    Hopital Beaujon, Clichy, France
    J Hepatol 52:32-8. 2010
  5. ncbi request reprint Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
  6. ncbi request reprint Natural history of hepatitis B
    P Marcellin
    INSERM U 481, Beaujon Hospital, Clichy, France
    Minerva Gastroenterol Dietol 51:63-75. 2005
  7. ncbi request reprint Medical therapy of patients affected by HBeAg-negative chronic hepatitis B
    P Marcellin
    Division of Hepatology and INSERM CRB3, University of Paris VII, Beaujon Hospital, Clichy, France
    Minerva Gastroenterol Dietol 52:23-38. 2006
  8. ncbi request reprint [Management of hepatitis B and C]
    Patrick Marcellin
    Service d hépatologie et Inserm U481, Hopital Beaujon, 92110 Clichy
    Rev Prat 55:596-8. 2005
  9. ncbi request reprint [Treatment of chronic hepatitis B]
    Patrick Marcellin
    Service d hépatologie et Inserm U481, Hopital Beaujon, 92110 Clichy
    Rev Prat 55:624-32. 2005
  10. ncbi request reprint Treatment of chronic hepatitis B
    P Marcellin
    Service d Hepatologie, INSERM U 481 and Centre de Recherche Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    J Viral Hepat 12:333-45. 2005

Detail Information

Publications143 found, 100 shown here

  1. doi request reprint Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection
    Patrick Marcellin
    Hopital Beaujon, Clichy, France Electronic address
    Gastroenterology 145:790-800.e3. 2013
    ..We report the efficacy and safety of response-guided therapy with danoprevir (a potent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients...
  2. doi request reprint High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Hepatology 56:2039-50. 2012
    ..0-66.6%) among genotype 3 patients; and 59.4% (95% CI: 40.6-76.3%), 63.3% (95% CI: 54.3-71.6%), and 54.3% (95% CI: 47.5-60.9%) among genotype 4 patients. The absence of a VR by week 12 had the highest negative PV across all genotypes...
  3. doi request reprint Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
  4. doi request reprint Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients
    Patrick Marcellin
    Hopital Beaujon, Clichy, France
    J Hepatol 52:32-8. 2010
    ..Viramidine is associated with a lower incidence of anemia because of its liver-targeting properties...
  5. ncbi request reprint Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
    ..As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications...
  6. ncbi request reprint Natural history of hepatitis B
    P Marcellin
    INSERM U 481, Beaujon Hospital, Clichy, France
    Minerva Gastroenterol Dietol 51:63-75. 2005
    ..Patients with decompensated cirrhosis have a poor prognosis (14-35% probability of survival at 5 years). HBV-related end-stage liver disease or HCC are responsible for at least 500,000 deaths per year...
  7. ncbi request reprint Medical therapy of patients affected by HBeAg-negative chronic hepatitis B
    P Marcellin
    Division of Hepatology and INSERM CRB3, University of Paris VII, Beaujon Hospital, Clichy, France
    Minerva Gastroenterol Dietol 52:23-38. 2006
    ....
  8. ncbi request reprint [Management of hepatitis B and C]
    Patrick Marcellin
    Service d hépatologie et Inserm U481, Hopital Beaujon, 92110 Clichy
    Rev Prat 55:596-8. 2005
  9. ncbi request reprint [Treatment of chronic hepatitis B]
    Patrick Marcellin
    Service d hépatologie et Inserm U481, Hopital Beaujon, 92110 Clichy
    Rev Prat 55:624-32. 2005
    ..However, one may expect that their use in monotherapy could not induce a high rate of sustained response and that long-term therapy or combination should be needed to improve efficacy and/or reduce resistance...
  10. ncbi request reprint Treatment of chronic hepatitis B
    P Marcellin
    Service d Hepatologie, INSERM U 481 and Centre de Recherche Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    J Viral Hepat 12:333-45. 2005
    ....
  11. ncbi request reprint Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C
    Patrick Marcellin
    Hopital Beaujon, Service d Hepatologie, 100 Bld du General Leclerc, 92100 Clichy, France
    J Hepatol 47:476-83. 2007
    ..In the hepatitis C virus (HCV) replicon system, merimepodib (MMPD), a novel, selective inhibitor of inosine monophosphate dehydrogenase, has shown potent antiviral effects...
  12. ncbi request reprint High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients
    Patrick Marcellin
    Hopital Beaujon, Service d Hepatologie, Clichy, France
    Eur J Gastroenterol Hepatol 22:1290-6. 2010
    ..This study describes the types of therapy used in chronic hepatitis B (CHB) in France and patient characteristics according to therapy...
  13. doi request reprint Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
    Patrick Marcellin
    Service d Hepatologie, U773 CRB3, Hopital Beaujon, University of Paris, Clichy, France
    Gastroenterology 136:2169-2179.e1-4. 2009
    ..The durability of <or=3-year posttreatment response was investigated in this study...
  14. doi request reprint Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
    ..We assessed the influence of combination therapy on the risk of HCC, liver-related complications (ascites, variceal bleeding), and liver-related death (or liver transplantation)...
  15. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Service d Hepatologie, INSERM CRB3, Universite Paris VII, Hopital Beaujon, Clichy 92
    Presse Med 35:327-34. 2006
    ..They induce a sustained response after withdrawal of therapy in only a minority of patients and therefore the treatment needs to be indefinitely administered in the majority of patients...
  16. doi request reprint Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy, France
    Antivir Ther 14:1183-8. 2009
    ....
  17. doi request reprint Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy F 92110, France
    Gastroenterology 134:416-23. 2008
    ..Our study was designed to test the association between insulin resistance (IR) and hepatitis C virus (HCV) genotypes, serum HCV RNA level and liver fibrosis stage in a large prospective cohort of chronic hepatitis C (CHC) patients...
  18. ncbi request reprint Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin
    Valerie Paradis
    Service d anatomie pathologie, Hopital Beaujon, and CNRS UMR 8149, Clichy, France
    Gastroenterology 130:2189-97. 2006
    ..We used this approach to monitor the kinetics of serum proteome in patients with chronic hepatitis C virus infection receiving a standard bitherapy regimen to predict treatment response...
  19. doi request reprint Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..HBsAg loss was observed in three patients, all with SVR...
  20. doi request reprint High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, 100 Boulevard du General Leclerc, 92100 Clichy, France
    J Hepatol 50:1084-92. 2009
    ..To assess the HBsAg seroconversion rate and its impact on the long-term outcome in chronic hepatitis B patients treated with conventional interferon, and to analyze the serum HBsAg concentration prior to seroconversion...
  21. ncbi request reprint Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Antivir Ther 14:501-11. 2009
    ....
  22. doi request reprint Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
    Sarah Maylin
    Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterology 135:821-9. 2008
    ..It is unclear whether hepatitis C virus (HCV) is eradicated in patients with chronic hepatitis C who achieved a sustained virologic response (SVR)...
  23. ncbi request reprint High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy
    Rami Moucari
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, AP HP, Universite Paris VII, Clichy, France
    J Hepatol 46:596-604. 2007
    ..To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of trials, who were relapsers or non-responders to interferon and ribavirin combination...
  24. pmc Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009
    ..Viral eradication in chronic hepatitis C patients with sustained virological response (SVR) after interferon (IFN) therapy remains controversial...
  25. doi request reprint Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
    Rami Moucari
    Service d Hépatologie et INSERM U773 CRB3, Hopital Beaujon, Clichy, France
    Gut 59:1694-8. 2010
    ..The aim of this study was to evaluate the short-term effect of an HCV protease inhibitor monotherapy on IR in parallel with an antiviral effect...
  26. ncbi request reprint Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B
    Vincent Di Martino
    Service d Hepatologie, INSERM U481 et Centre de Recherche Claude Bernard sur les hépatites virales, Hôpital Beaujon AP HP, Clichy, France
    Gastroenterology 123:1812-22. 2002
    ..We analyzed the influence of HIV coinfection on the response to IFN-alpha therapy, long-term virologic status, progression to cirrhosis, and mortality...
  27. doi request reprint Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Antivir Ther 17:61-70. 2012
    ..The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of HBV genomes directly isolated from patients' sera...
  28. doi request reprint The role of HBsAg quantification for monitoring natural history and treatment outcome
    Michelle Martinot-Peignoux
    INSERM, U 773, CRB3, Universite Paris Diderot, Hopital Beaujon, Clichy, France
    Liver Int 33:125-32. 2013
    ..In clinical practice, HBsAg quantification is a simple and reproducible tool that can be used in association with HBV DNA to classify patients during the natural history of HBV and to monitor therapy...
  29. pmc Impact of ribavirin dose on retreatment of chronic hepatitis C patients
    Christiane Stern
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, University Paris Diderot, 92110 Clichy, France
    World J Gastroenterol 18:2966-72. 2012
    ..To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients...
  30. ncbi request reprint Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study
    Pierre Bedossa
    Service d Anatomie Pathologique, CNRS UMR 8149, Clichy, France
    Hepatology 46:380-7. 2007
    ..In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor...
  31. doi request reprint Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
    Patrick Marcellin
    Hopital Beaujon, Assistance Publique Hopitaux de Paris, University of Paris 7 and INSERM Unité 773, Centre de Recherches Claude Bernard sur les Hepatites Virales, Clichy, France
    N Engl J Med 359:2442-55. 2008
    ..Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase...
  32. doi request reprint Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomédicale Bichat Beaujon CRB3 and Service d Hépatologie, Hopital Beaujon, AP HP, Universite Paris 7, 92110 Clichy, France
    J Clin Virol 46:216-21. 2009
    ..Early viral monitoring is essential for the management of treatment outcome in patients with chronic hepatitis C. A variety of commercially available assays are now available to quantify HCV-RNA in routine clinical practice...
  33. ncbi request reprint Role of replicative senescence in the progression of fibrosis in hepatitis C virus (HCV) recurrence after liver transplantation
    Viviane Trak-Smayra
    Service d Anatomie Pathologique, Hopital Beaujon, Clichy, France
    Transplantation 77:1755-60. 2004
    ....
  34. ncbi request reprint A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 40:140-8. 2004
    ..The pharmacokinetic profile of clevudine was proportional to the dose. In conclusion, these results demonstrate the tolerability and potent activity of clevudine in HBV-infected patients and support further clinical study...
  35. doi request reprint Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Hopital Beaujon, Paris, France
    Hepatology 48:750-8. 2008
    ..Adefovir resistance mutations A181V or N236T developed in 13 LTSES patients; the first observation was at study week 195. There were no serious adverse events related to ADV...
  36. ncbi request reprint Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection
    Pierre Emmanuel Rautou
    Service d hépatologie and INSERM CRB3, University of Paris VII, Hopital Beaujon, Clichy, France
    Eur J Gastroenterol Hepatol 18:1019-22. 2006
    ..We conclude that the combination of PegIFN plus ribavirin may induce suppression of both viral infections...
  37. ncbi request reprint Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University Paris 7, Hopital Beaujon, Clichy, France
    J Hepatol 47:580-7. 2007
    ..32% with 48 weeks, P=0.014). Patients are best served by quantitative determination of the hepatitis C virus RNA level at weeks 4, 12 and 24. The results of these determinations can then be used to tailor the length of therapy...
  38. doi request reprint Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies
    Patrick Marcellin
    Hopital Beaujon, 100 Boulevard du General Leclerc, Clichy, 92110, France
    Expert Opin Drug Saf 11:901-9. 2012
    ..This analysis examines the safety profile of standard- versus high-dose peginterferon alfa-2a...
  39. ncbi request reprint Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C
    M Martinot-Peignoux
    INSERM U481, Service d Hepatologie, Hopital Beaujon, Clichy, France
    J Viral Hepat 13:701-7. 2006
    ..A week 4 stopping rule for patients with chronic hepatitis C treated with peginterferon with ribavirin might be proposed by using the model developed in our study...
  40. pmc Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue
    Tarik Asselah
    Service d Hépatologie and Institut National de la Santé et de la Recherche Médicale INSERM U733, CRB3, Universite Paris Diderot, Assistance Publique Hopitaux de Paris, Hopital Beaujon, Clichy, France
    Hepatology 48:953-62. 2008
    ..In chronic hepatitis C liver samples, a lower or higher expression of a IL8 was found depending on whether the controls were obtained percutaneously or surgically...
  41. doi request reprint Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon
    Patrick Marcellin
    Service d Hepatologie, INSERM CRB3, Hopital Beaujon, APHP University of Paris 7, Clichy, France
    Liver Int 30:657-68. 2010
    ....
  42. doi request reprint Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773 and Service d Hépatologie Hôpital Beaujon APHP, Universite Paris Diderot, 92110 Clichy, France
    J Hepatol 58:1089-95. 2013
    ..Therefore, we investigated these relationships in a large cohort of unselected, well-characterized, treatment-naïve CHB patients...
  43. ncbi request reprint [Chronic hepatitis B: which patients should be treated and how?]
    Tarik Asselah
    Hepatologie, INSERM U481, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 29:374-83. 2005
  44. doi request reprint Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C
    Ana Carolina Cardoso
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, APHP, University of Paris 7, Clichy, France
    Liver Int 32:612-21. 2012
    ..A secondary analysis was performed to assess whether or not alanine aminotransferase (ALT) levels would impact on the accuracy of TE...
  45. ncbi request reprint [Treatment of patients with chronic hepatitis C who have not been previously treated]
    Patrick Marcellin
    Service d Hepatologie, INSERM U 481 et Centre Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy
    Gastroenterol Clin Biol 26:B194-201. 2002
  46. ncbi request reprint Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C
    Tarik Asselah
    Service d Hépatologie and INSERM U773, CRB3, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Semin Liver Dis 27:13-27. 2007
    ..This article reviews genetic, genomic, and proteomic aspects associated with the natural history of HCV infection (i.e., viral clearance, fibrosis progression) and the response to therapy...
  47. doi request reprint Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    Thierry Poynard
    Service d Hepatologie, Université Pierre et Marie Curie Liver Center, hôpital La Pitié Salpêtrière, Paris, France
    Gastroenterology 136:1618-28.e2. 2009
    ..Alternate options are needed for patients who relapse or do not respond to therapy...
  48. ncbi request reprint Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up
    Corinne Castelnau
    Service d Hepatologie, Hopital Beaujon, AP HP INSERM U773 CRB3, Clichy, and Université Paris 13, Bobigny, France
    Hepatology 44:728-35. 2006
    ..The follow-up of HDV-RNA levels during therapy, which allows the differentiation of various profiles of virological responses, improves treatment monitoring...
  49. doi request reprint Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Pavillon Abrami, 100 Boulevard Général Leclerc, 92110 Clichy, France
    J Hepatol 56:1276-82. 2012
    ....
  50. doi request reprint IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    J Hepatol 56:527-32. 2012
    ..However, there are few data on HCV genotype 4 (HCV-4) infection. We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity...
  51. doi request reprint Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Liver Int 32:93-101. 2012
    ..To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir...
  52. ncbi request reprint Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma
    Chiara Viola
    Service d Hepatologie, INSERM CRB3, University of Paris VII, Hopital, Beaujon, Clichy 92 110, France
    World J Gastroenterol 12:4911-3. 2006
    ..Many HCCs grow slowly, and the growth rate of recurrent tumors in patients receiving immunosuppressive therapy is significantly greater than that of those who do not receive immunosuppressive therapy...
  53. ncbi request reprint Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481, and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 348:808-16. 2003
    ..In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains...
  54. ncbi request reprint Interferon therapy for chronic hepatitis B
    Tarik Asselah
    Service d Hepatologie, INSERM U773, CRB3, University of Paris VII, Hopital Beaujon, 92110 Clichy, France
    Clin Liver Dis 11:839-49, viii. 2007
    ..This article summarizes the results obtained with interferon alfa and pegylated interferon alfa, as monotherapy and in combination with lamivudine, in the treatment of chronic hepatitis B...
  55. doi request reprint Interferon free therapy with direct acting antivirals for HCV
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 33:93-104. 2013
    ....
  56. pmc Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy
    Liana Codes
    Service d Hepatologie, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Gut 56:390-5. 2007
    ..The aim of this study was to evaluate the severity of chronic hepatitis C in women, in relation to the menopause, steatosis and hormone replacement therapy (HRT)...
  57. doi request reprint Protease and polymerase inhibitors for the treatment of hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Service d Hepatologie, Hopital Beaujon, Clichy, France
    Liver Int 29:57-67. 2009
    ..The development of new molecules such as HCV enzyme inhibitors is ongoing. The aim of this review is to summarize results obtained with STATC: protease and polymerase inhibitors...
  58. ncbi request reprint Acute hepatitis E with severe jaundice: report of three cases
    Rami Moucari
    Hepatology Department and INSERM U773, CRB3, University of Paris VII, Beaujon Hospital, Clichy, France
    Eur J Gastroenterol Hepatol 19:1012-5. 2007
    ..HEV-RNA detection by real-time reverse transcriptase-PCR is a very efficacious diagnostic tool in anti-HEV immunoglobulin-M-negative cases...
  59. doi request reprint Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, INSERM Unit CRB3, Clichy, France
    Lancet 381:468-75. 2013
    ..We aimed to assess the effects on fibrosis and cirrhosis of at least 5 years' treatment with tenofovir disoproxil fumarate (DF) in chronic HBV infection...
  60. doi request reprint Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, APHP, Universite Denis Diderot Paris 7, Clichy, France
    Gastroenterology 140:459-468.e1; quiz e14. 2011
    ..We investigated the efficacy, safety, tolerability, and pharmacokinetics of telaprevir given q8h or every 12 hours (q12 h) in combination with peginterferon alfa-2a or alfa-2b...
  61. doi request reprint Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Liver Int 32:88-102. 2012
    ..The aim of this review is to summarize mechanisms of action and results obtained with DAAs...
  62. pmc SCG10 expression on activation of hepatic stellate cells promotes cell motility through interference with microtubules
    Valerie Paradis
    Department of Pathology, INSERM U773, the Serviced Hépatologie, Beaujon Hospital, AP HP, University Paris Diderot, Paris, France
    Am J Pathol 177:1791-7. 2010
    ..SCG10 may represent a potential molecular target for anti-fibrosis therapies...
  63. doi request reprint Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study
    Patrick Marcellin
    Department of Hepatology, University of Paris 7, INSERM U 773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 31:516-24. 2011
    ..Adherence is important for therapy of chronic diseases, but has still not been well studied in real life in chronic hepatitis C...
  64. doi request reprint New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, and Service d Hépatologie, Hopital Beaujon, Clichy, France
    Liver Int 31:68-77. 2011
    ..There is ongoing development of new molecules such as HCV enzyme inhibitors. The aim of this review is to summarize the results obtained with DAAs: protease and polymerase inhibitors...
  65. ncbi request reprint [HCV non-responder patients: definition of non-response and treatment strategy]
    Patrick Marcellin
    Service d Hepatologie, INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 31:4S13-9. 2007
    ..The drugs, currently in phase 1 and 2, which will demonstrate their efficacy and safety, should not be available before several years...
  66. doi request reprint Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B
    Patrick Marcellin
    Service d Hépatologie and INSERM U 773, Hopital Beaujon, AP HP, University of Paris, Clichy, France
    Liver Int 29:242-7. 2009
    ..This study aims to assess its diagnosis accuracy in patients with chronic hepatitis B...
  67. ncbi request reprint Clevudine: a promising therapy for the treatment of chronic hepatitis B
    Tarik Asselah
    Universite Paris 7 Denis Diderot, Hopital Beaujon, Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U773
    Expert Opin Investig Drugs 17:1963-74. 2008
    ..This article reviews chronic HBV and its therapy options. Specifically, it describes clevudine's potent and sustained antiviral activity as observed in vitro and in vivo...
  68. ncbi request reprint [New management strategies for hepatitis B]
    Corinne Castelneau
    Service d Hepatologie, Inserm U 481 et Centre de recherche Claude Bernard sur les hépatites virales, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 26:120-2. 2002
  69. doi request reprint Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4
    R Moucari
    Hopital Beaujon, 92110 Clichy, France
    Gut 58:1662-9. 2009
    ....
  70. ncbi request reprint [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]
    Rami Moucari
    Pôle des Maladies de l Appareil Digestif, Service d Hépatologie et INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy
    Gastroenterol Clin Biol 31:643-54. 2007
    ..Insulin resistance and steatosis, appear to be associated with fibrosis progression and impairment of sustained response to antiviral treatment...
  71. ncbi request reprint The current status of antiviral therapy of chronic hepatitis B
    Tarik Asselah
    Seroice d Hépatologie and INSERM CRB3, Unioersity Paris 7, Hopital Beaujon, AP HP, Clichy, France
    J Clin Virol 34:S115-24. 2005
    ....
  72. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Service d Hepatologie, INSERM U481, Hopital Beaujon, 92110 Clichy
    Gastroenterol Clin Biol 28:1215-27. 2004
  73. ncbi request reprint The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study
    V Di Martino
    , , , Clichy, France
    Hepatology 34:1193-9. 2001
    ..Age and alcohol were cofactors associated with cirrhosis and mortality. Interferon therapy had a protective effect against HCV-related cirrhosis no matter what the patient's HIV status was...
  74. ncbi request reprint Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C
    Tarik Asselah
    Service d hépatologie and INSERM CRB3, AP HP Hôpital Beaujon, University of Paris VII, Paris, France
    Gastroenterology 129:2064-75. 2005
    ....
  75. pmc Changes in autophagic response in patients with chronic hepatitis C virus infection
    Pierre Emmanuel Rautou
    Service d Hepatologie, Hopital Beaujon, Assistance Publique Hopitaux de Paris, Clichy, France
    Am J Pathol 178:2708-15. 2011
    ..Neither genotype nor viral load influenced the autophagy level. In conclusion, autophagy is altered in hepatocytes from CHC patients, likely due to a blockade of the last step of the autophagic process...
  76. ncbi request reprint Advances in therapy for chronic hepatitis B
    Patrick Marcellin
    Service d Hépatologie and INSERM 0481, Hopital Beaujon, Clichy, France
    Semin Liver Dis 22:33-6. 2002
    ..Adefovir dipivoxil's effects include rapid and sustained virological, serological, histological, and biochemical responses, with minimal adverse effects. Significant histological improvement was seen in all patient subgroups at 48 weeks...
  77. ncbi request reprint Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment
    A Gervais
    , , Hĵpital Beaujon AP-HP, Clichy, France
    J Hepatol 35:399-405. 2001
    ..CONCLUSIONS: The amount of hepatic HCV-RNA is correlated to genotype and response to interferon therapy but not to histologic lesions. Hepatic HCV-RNA clearance is observed in SRs, suggesting viral eradication...
  78. pmc Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C
    T Asselah
    Centre de Recherche Claude Bernard sur les Hépatites Virales, AP HP Hôpital Beaujon, Clichy, France Service de Biochimie, AP HP Hôpital Beaujon, Clichy, France
    Gut 52:1638-43. 2003
    ....
  79. ncbi request reprint Hepatitis C: the clinical spectrum of the disease
    P Marcellin
    Centre de Recherche Claude Bernard sur les Hépatites Virales and INSERM U 481, Hopital Beaujon, Clichy, France
    J Hepatol 31:9-16. 1999
    ..In patients with HCV-related cirrhosis, the incidence of hepatocellular carcinoma is 2-5% per year. At presently, HCV-related end-stage cirrhosis is the first cause of liver transplantation...
  80. ncbi request reprint Fibrosis and disease progression in hepatitis C
    Patrick Marcellin
    Service d Hépatologie and INSERM U 481, Hopital Beaujon, Clichy, France
    Hepatology 36:S47-56. 2002
    ..Repeating the liver biopsy, 3 to 5 years after an initial biopsy is the most accurate means of assessing the progression of fibrosis...
  81. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Hopital Beaujon, Service d Hepatologie, AP HP, 92110 Clichy
    Rev Prat 61:45-51. 2011
    ..Telbivudine is more potent and has a lower rate of resistance than lamivudine but the resistance rate is significantly higher than other approved drugs. Tenofovir has a potent antiviral effect with a good resistance profile...
  82. ncbi request reprint Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers
    Michelle Martinot-Peignoux
    Unité de Recherche INSERM U 481, Centre de Recherche Claude Bernard sur les Hépatites Virales and Service d Hépatologie, Hopital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 36:543-6. 2002
    ..The new definition inactive surface antigen (HBsAg) carriers includes an estimated serum HBV DNA level below 105 copies/ml. However, this cut-off value needs to be confirmed...
  83. ncbi request reprint Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C
    Michel Tod
    Department of Pharmacy, Cochin St Vincent de Paul Hospital, Paris, France
    Clin Pharmacokinet 44:417-28. 2005
    ..Interferon (IFN)-alpha and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C. However, ribavirin induces anaemia, especially by haemolysis, an adverse effect that is dose-limiting...
  84. ncbi request reprint Auxiliary liver transplantation for fulminant hepatitis B: results from a series of six patients with special emphasis on regeneration and recurrence of hepatitis B
    Francois Durand
    Service d Hépatologie and INSERM U481, Hopital Beaujon, Clichy, France
    Liver Transpl 8:701-7. 2002
    ..Finally, the remnant part of the native liver does not compromise immunization against HBV...
  85. ncbi request reprint Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases
    Nathalie Ganne-Carrie
    Hépato Gastroentérologie, Hopital Jean Verdier, Bondy, France UPRES EA3409, Universite Paris 13, Bobigny, France
    Hepatology 44:1511-7. 2006
    ..6 kPa. False-negatives are mainly attributable to inactive or macronodular cirrhosis...
  86. ncbi request reprint Haemobilia causing acute pancreatitis after percutaneous liver biopsy: diagnosis by magnetic resonance cholangiopancreatography
    T Asselah
    Service d Hepatologie, INSERM U 481 and Centre de Recherche Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    Eur J Gastroenterol Hepatol 13:877-9. 2001
    ..We present a case of haemobilia causing acute pancreatitis after percutaneous liver biopsy in which the diagnosis could be made clearly by MRCP, thus avoiding endoscopic retrograde cholangiopancreatography and sphincterotomy...
  87. pmc Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays
    M Martinot-Peignoux
    Unité de Recherche INSERM U481, Centre de Recherche Claude Bernard sur les Hépatites Virales and Service d Hépatologie, Hopital Beaujon, 92110 Clichy, France
    J Clin Microbiol 38:2722-5. 2000
    ..Our results indicate that COBAS HCV MONITOR version 2.0 and QUANTIPLEX HCV RNA version 2.0 assays showing an equal dynamic range for each HCV genotype are suitable tools to assess patients before therapy...
  88. ncbi request reprint [Treatment of hepatitis B]
    P Marcellin
    Service d Hepatologie, Inserm U 481 et Centre de recherche Claude Bernard sur les hépatites virales, Hopital Beaujon, 93000 Clichy, France
    Rev Med Interne 23:535s-536s. 2002
  89. ncbi request reprint Ectopic hepatocellular carcinoma arising in the left chest wall: a long-term follow-up
    T Asselah
    Service d Hepatologie, Hopital Beaujon, 100 Bd du Gal Leclerc, 92118 Clichy, France
    Eur J Gastroenterol Hepatol 13:873-5. 2001
    ..We conclude that solitary extrahepatic HCC (i) may arise in ectopic liver tissue; (ii) should not be considered as a metastasis of an occult HCC; and (iii) can be amenable to cure through resection...
  90. ncbi request reprint Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis
    F Marrache
    Service d Hepatologie, Inserm U 481 and Claude Bernard Research Center on Viral Hepatitis, Hopital Beaujon, Clichy, France
    J Viral Hepat 12:421-8. 2005
    ..This therapy is safe with appropriate monitoring, but tolerance seems worse in patients with the most advanced liver disease...
  91. ncbi request reprint Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels
    T Asselah
    Service d Hepatologie, INSERM U 481 and Centre de Recherche Claude Bernard sur les Hépatites Virales, Clichy, France
    J Viral Hepat 9:29-35. 2002
    ..These results are consistent with the view that patients with normal ALT have a different immune response against HCV resulting in a low HCV heterogeneity...
  92. pmc Treatment of hepatitis C. The 2002 French consensus
    D Dhumeaux
    Department of Hepatology and Gastroenterology, Henri Mondor Hospital, Creteil, France
    Gut 52:1784-7. 2003
  93. ncbi request reprint Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA
    M Martinot-Peignoux
    Unité de Recherche INSERM U481, Centre de Recherche Claude Bernard sur les Hépatites Virales and Service d Hépatologie, Hopital Beaujon, Clichy, France
    Hepatology 34:1000-5. 2001
    ..During follow-up, the HCV RNA status of patients remained unchanged; 21% of the patients with detectable serum HCV RNA had slight increase in serum ALT levels, but histological lesions remained stable...
  94. ncbi request reprint HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C
    Vincent Di Martino
    Service d Hepatologie, INSERM U481 et Centre de Recherche Claude Bernard sur les hépatites virales, 100 bd du Général Leclerc, Hopital Beaujon, 92110 Clichy, France
    AIDS 16:441-5. 2002
    ..We compared histological responses to interferon (IFN) alpha therapy between HIV-positive and HIV-negative injecting drug users (IDU) and determined factors associated with histological response...
  95. pmc Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy
    T Asselah
    Service d Hepatologie, INSERM U 481 and Centre de Recherche Claude Bernard sur les Hépatites Virales, Clichy, France
    Gut 52:900-2. 2003
    ..An alternative explanation is that IFN, while not preventing acute hepatitis C, may prevent chronicity. The risk of multiple infection in IVDU underlines the need for preventive strategies...
  96. pmc Steatosis in chronic hepatitis C: why does it really matter?
    T Asselah
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, Clichy 92110, France
    Gut 55:123-30. 2006
    ..This review describes and discusses the basic and clinical aspects of the relationship between steatosis and progression of fibrosis, and response to treatment in patients with chronic hepatitis C...
  97. ncbi request reprint Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
    T Asselah
    Service d Hepatologie, Pôle des Maladies de l Appareil Digestif and INSERM U773, CRB3, University of Paris VII, AP HP Beaujon Hospital, Clichy, France
    Gut 57:516-24. 2008
    ..Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of this study was to identify a liver gene signature to predict sustained virological response in patients with CHC...
  98. ncbi request reprint Management of chronic hepatitis C
    T Asselah
    Service d Hépathologie and INSERM U 773, University of Paris VII, Beaujon Hospital, Clichy, France
    Minerva Gastroenterol Dietol 53:9-23. 2007
    ..This paper will discuss the natural history, the factors associated with the progression of fibrosis, the predictive factors of response to treatment, and existing and future treatments for hepatitis C...
  99. ncbi request reprint Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C
    A Gervais
    Service d Hepatologie, INSERM U481 and Centre de Recherche Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    J Hepatol 32:293-9. 2000
    ..The natural history of chronic hepatitis C infection during pregnancy has not been clearly established, and thus our aim was to assess serum alanine aminotransferase levels and serum HCV RNA levels during pregnancy...
  100. ncbi request reprint A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C
    M Martinot-Peignoux
    Unité de Recherche INSERM U481, Hopital Beaujon, Clichy, France
    Hepatology 31:726-9. 2000
    ....
  101. pmc Quantitative measurement of hepatitis C virus core antigen is affected by the presence of cryoglobulins
    B N Pham
    Département d Immunologie Microbiologie des Pathologies Infectieuses, Hopital Beaujon, Clichy, France
    Clin Exp Immunol 146:211-7. 2006
    ..001). HCV parameter measurements and cryoglobulin study should not be performed on the same serum samples due to the potential impact of blood collection methods on results...